For permission requests, please contact NEJM Reprints at [email protected] We and others identified retinoblastoma features that suggested that the tumors originate in long- and medium-wavelength ...

Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results ...

Plant-based cheeses are marketed as safe alternatives to raw-milk cheese for populations at high risk for foodborne infection. Listeriosis cases in Europe, including in pregnancy, were linked to ...

A 35-year-old man received an incidental diagnosis of hypertension during a routine medical assessment. Computed tomographic angiography revealed aortic coarctation.

Adjuvant pembrolizumab was approved for patients with renal-cell carcinoma on the basis of improvements in disease-free survival observed in the KEYNOTE-564 trial. Data on overall survival are needed.

Mortality among young persons has risen, with firearm-related deaths disproportionately affecting Black youths. Firearm-related deaths now affect Black youths across both rural and urban settings.

The U.S. pharmaceutical market has always been influenced by government. The 2022 Inflation Reduction Act is the latest policy aiming to improve access and affordability while supporting innovation.

Most physicians now face the experience of being employees of hospitals or other large organizations. Unionization is a natural consequence of consolidation and the corporatization of health care ...

For patients with type 2 diabetes, there are no approved treatments that specifically target obesity-related heart failure with preserved ejection fraction. New research findings are summarized in ...

PHILIP COOMBS KNAPP, A.M., M.D. Copying failed.

A shortage of GLP-1 receptor agonists and other drugs raises questions about how limited supplies should be allocated. A proposed framework could guide governments, professional societies, and ...

Surgery with curative intent constitutes the standard of care for patients with advanced renal-cell carcinoma, yet more than 50% of patients with high-risk features will have disease recurrence.